Overview
On April 17, 2020 partner Benjamin Greenblum published an article titled “Courts Grappling with Antitrust Challenges to Orange Book Listings” in Law360’s Expert Analysis series. The article discusses the potential risk of antitrust liability for pharmaceutical companies listing patents in the FDA’s Orange Book and how the courts are addressing these issues.
Click here to read the article.